Community-acquired pneumonia primary prevention: Difference between revisions
Jump to navigation
Jump to search
Line 9: | Line 9: | ||
| style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px"| '''Factor''' || style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px" | '''Pneumococcal polysaccharide vaccine''' | | style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px"| '''Factor''' || style="background: #A5B2D6; border: 0px solid #696969; padding: 0 5px; width: 200px" | '''Pneumococcal polysaccharide vaccine''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Route of administration''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Intramuscular injection''''' | | style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Route of administration''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''Intramuscular injection''''' | ||
|- | |- | ||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Type of vaccine''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''Bacterial component (polysaccharide capsule)''''' | | style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Type of vaccine''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left | ▸'''''Bacterial component (polysaccharide capsule)''''' | ||
Line 19: | Line 19: | ||
| style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Revaccination schedule''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''One-time revaccination after 5 years for <br> ▸ (1) adults 65 years of age, if the first dose is received before age 65 years<br> ▸ (2) persons with asplenia <br>▸ (3) immunocompromised persons''''' | | style="font-size: 90%; padding: 0 5px; background: #F5F5F5" align=left | ▸ '''''Revaccination schedule''''' || style="font-size: 90%; padding: 0 5px; background: #DCDCDC" align=left |▸ '''''One-time revaccination after 5 years for <br> ▸ (1) adults 65 years of age, if the first dose is received before age 65 years<br> ▸ (2) persons with asplenia <br>▸ (3) immunocompromised persons''''' | ||
|- | |- | ||
|} | |} | ||
Adapted from the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention.<ref name="Harper-2005">{{Cite journal | last1 = Harper | first1 = SA. | last2 = Fukuda | first2 = K. | last3 = Uyeki | first3 = TM. | last4 = Cox | first4 = NJ. | last5 = Bridges | first5 = CB. | title = Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). | journal = MMWR Recomm Rep | volume = 54 | issue = RR-8 | pages = 1-40 | month = Jul | year = 2005 | doi = | PMID = 16086456 }}</ref> | Adapted from the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention.<ref name="Harper-2005">{{Cite journal | last1 = Harper | first1 = SA. | last2 = Fukuda | first2 = K. | last3 = Uyeki | first3 = TM. | last4 = Cox | first4 = NJ. | last5 = Bridges | first5 = CB. | title = Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP). | journal = MMWR Recomm Rep | volume = 54 | issue = RR-8 | pages = 1-40 | month = Jul | year = 2005 | doi = | PMID = 16086456 }}</ref> |
Revision as of 21:28, 29 January 2014
Community-Acquired Pneumonia Microchapters |
Differentiating Community-acquired pneumonia from other Diseases |
Diagnosis |
Treatment |
Case Studies |
Community-acquired pneumonia primary prevention On the Web |
American Roentgen Ray Society Images of Community-acquired pneumonia primary prevention |
Directions to Hospitals Treating Community-acquired pneumonia |
Risk calculators and risk factors for Community-acquired pneumonia primary prevention |
Vaccines
Pneumococcal Polysaccharide Vaccine
Factor | Pneumococcal polysaccharide vaccine |
▸ Route of administration | ▸ Intramuscular injection |
▸ Type of vaccine | ▸Bacterial component (polysaccharide capsule) |
▸ Recommended groups | ▸All persons ≥ 65 years of age 'High-risk persons 2–64 years of age' 'Current smokers' |
▸ Specific high-risk indications for vaccination | ▸ Chronic cardiovascular, pulmonary, renal, or liver disease ▸Diabetes mellitus ▸Cerebrospinal fluid leaks ▸ Alcoholism ▸ Asplenia ▸ Immunocompromising conditions / medications ▸Native Americans and Alaska natives ▸Long-term care facility residents |
▸ Revaccination schedule | ▸ One-time revaccination after 5 years for ▸ (1) adults 65 years of age, if the first dose is received before age 65 years ▸ (2) persons with asplenia ▸ (3) immunocompromised persons |
Adapted from the Advisory Committee on Immunization Practices, Centers for Disease Control and Prevention.[1]